Previous 10 | Next 10 |
home / stock / esaly / esaly news
Eisai: New Data on LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus Sunitinib TOKYO and KENILWORTH, N.J., June 8, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. announced new investigational data from the pivotal Phase 3 CL...
The long wait for a disease-modifying treatment option for millions of Americans suffering from Alzheimer's disease is finally over. The FDA on Monday approved aducanumab from Biogen (NASDAQ: BIIB) and its longtime collaboration partner Eisai (OTC: ESALY) . Biogen will marke...
Biotech heavyweight Biogen (NASDAQ: BIIB) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug Administration approval of its controversial Alzheimer's disease drug aducanumab. The biotech's par...
Merck (MRK) and Eisai (ESALF) announce new investigational data from the Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, evaluating the combinations of Keytruda, plus Eisai's Lenvima, and Lenvima plus everolimus vs. sunitinib for the first-line treatment of patients with advanced renal cell...
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia TOKYO, May 31, 2021 - (JCN Newswire) - Eisai Co., Ltd. and ITO EN, LTD. announced today that both parties have entered into a business alliance agreement concern...
Eisai to Present Data on Oncology Pipeline and Products at ASCO Annual Meeting TOKYO, May 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the latest data regarding its oncology pipeline and products including in-house discovered lenvatinib mesylate (multikinas...
Recent advances in understanding how soluble amyloid oligomers drive Alzheimer’s disease and new biomarkers are supporting the development of effective treatments that will reach the market in the near future. These scientific developments also provide a new way for investors t...
Eisai and National Cancer Center Commence Joint Research and Development Project TOKYO, May 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. and the National Cancer Center Japan announced today that both parties have entered into a joint research and development (R&D) agreement...
Eisai Co., Ltd. (ESALF) Q4 2021 Earnings Conference Call May 12, 2021 03:00 AM ET Company Participants Haruo Naito - CEO Ryohei Yanagi - EVP & CFO Ivan Cheung - SVP & President of Neurology Business Group Takashi Owa - Chief Medicine Creation Officer & Chief Discovery Officer Onco...
The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2021 Q4 earnings call. For further details see: Eisai Co., Ltd. 2021 Q4 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...